Strainprint President & CTO, David Berg Featured in Cannabis Investing News

Written by Strainprint

The legalization of cannabis has allowed researchers to begin investigating the drug at more in-depth levels than before.

With the current state of cannabis working towards legalization across the globe, new channels of research are opening up across the board as an effort to rapidly catch up with a market ready to consume a product it doesn’t know everything about.

Read on to hear what Strainprint, President & CTO, David Berg had to say…..

Cannabis & Opioids: An Interview with Dr. Peter Grinspoon

Coinciding with the adult use legalization of cannabis across North America, an opioid epidemic has emerged. It is estimated that more than 130 people die each day due to opioid overdose in the United States alone, according to the U.S. Department of Health and Human Services (HHS). The organization reported that, in 2017, nearly 50,000 Americans died […]

Understanding Terpenes: Camphene

Camphene, sometimes called comphene, is one of more than 200 terpenes discovered to date in hemp and cannabis. Terpenes are aromatic molecules once thought to convey only aroma and, from an evolutionary functional perspective, to protect a plant from pests and predators. In recent years, however, much clinical research, in addition to anecdotal evidence, has […]

Understanding Terpenes — Beta-Caryophyllene

Welcome to the Strainprint Community Understanding Terpenes Series. Before diving into the details behind beta-caryophyllene (BCP, caryophyllene, or β-caryophyllene), the molecule produced by cannabis known for its categorization as both a terpene and a cannabinoid that provides pain killing and anti-inflammatory benefits, it behooves readers to develop a solid understanding of terpenes as a category of wellness molecule. Patients […]